Publications by authors named "M Humam Zaim Faruqi"
Background: Coal worker's pneumoconiosis (CWP) poses a significant burden on affected individuals and is associated with increased morbidity and mortality. Lung transplantation (LT) is the only effective treatment for this progressive and fatal lung disease. This study aims to evaluate the outcomes of patients who have undergone LT for primary diagnosis of CWP.
View Article and Find Full Text PDFAs an endocrine disruptor chemical, pesticide exposure may affect the regulation of growth hormones such as insulin-like growth factor-1 (IGF-1). A few current studies to date have noted that long-term pesticide exposure disrupted IGF-1, a potential risk of stunting in children. This study aims to evaluate studies to date of the effect of pesticide exposure on stunting incidence.
View Article and Find Full Text PDFArticle Synopsis
- Intrahepatic Cholestasis of Pregnancy (ICP) is a liver disorder that occurs in the second half of pregnancy, resulting in itching and abnormal liver function tests, with an incidence of 1.2-1.5% in India.
- The study aimed to analyze the relationship between liver transaminases and pregnancy outcomes in women with ICP and identify critical thresholds for predicting complications.
- Findings indicated that elevated ALT levels could predict adverse outcomes in pregnancy, suggesting that monitoring these levels could help in planning timely interventions.
Objective: We investigated the missed treatment opportunities affecting programmes using mid-upper arm circumference (MUAC) as the sole anthropometric criterion for identification and monitoring of children suffering from severe acute malnutrition (SAM).
Design: Alongside MUAC, we assessed weight-for-height -score (WHZ) in children screened and treated according to the national MUAC only protocol in Pakistan. Besides, we collected parents' perceptions regarding the treatment received by their children through qualitative interviews.
Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date.
Int J Chron Obstruct Pulmon Dis
January 2024
Article Synopsis
- - Ensifentrine is a new inhaler medication that targets specific enzymes (PDE3 and PDE4) to enhance bronchodilation and lower inflammation in the lungs, while causing few side effects throughout the rest of the body.
- - Research, including both preclinical and clinical trials, has shown that Ensifentrine can improve lung function and reduce the frequency of severe asthma or COPD episodes.
- - The US Food and Drug Administration is currently reviewing Ensifentrine, with a decision on its approval anticipated in 2024.